Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Vandetanib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 12 Jun 2008 New trial record.